Search results
Results from the WOW.Com Content Network
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share ...
Pfizer has licensed Halozyme Therapeutics' Enhanze technology, which the pharmaceutical giant plans to combine with its biologics. The technology allows drugs that would otherwise have to be ...
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...
Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting ...
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $152.4 million, +12% Y/Y, surpassing the consensus of $138.78 million. The increase was primarily driven by an increase in royalty ...
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their ...
Anyone researching Halozyme Therapeutics, Inc. (NASDAQ:HALO) might want to consider the historical volatility of the...